TABLE 4.
Nagelkerke’s R2 and Brier score of scoring models in patients with HBV–ACLF.
| Variates | 28-day |
90-day |
||
| Nagelkerke’s R2 (%) | Brier score |
Nagelkerke’s R2 (%) | Brier score |
|
| Total HBV-ACLF patients (n = 919) | ||||
| COSSH-ACLF IIs | 27.4 | 0.133 | 28.0 | 0.181 |
| COSSH-ACLFs | 22.2 | 0.140 | 24.3 | 0.184 |
| CLIF-C ACLFs | 22.6 | 0.140 | 20.9 | 0.194 |
| MELDs | 16.8 | 0.148 | 15.6 | 0.201 |
| MELD-Nas | 14.3 | 0.154 | 16.8 | 0.200 |
| TPPMs | 14.1 | 0.171 | 15.9 | 0.210 |
| All cirrhotic patients (n = 675) | ||||
| COSSH-ACLF IIs | 23.0 | 0.149 | 25.0 | 0.194 |
| COSSH-ACLFs | 16.8 | 0.157 | 21.0 | 0.198 |
| CLIF-C ACLFs | 19.1 | 0.154 | 18.4 | 0.205 |
| MELDs | 13.2 | 0.163 | 14.3 | 0.213 |
| MELD-Nas | 12.0 | 0.167 | 16.3 | 0.209 |
| TPPMs | 10.9 | 0.192 | 13.8 | 0.221 |
| All non-cirrhotic patients (n = 244) | ||||
| COSSH-ACLF IIs | 40.8 | 0.088 | 30.7 | 0.143 |
| COSSH-ACLFs | 40.4 | 0.091 | 27.2 | 0.146 |
| CLIF-C ACLFs | 32.4 | 0.105 | 23.1 | 0.160 |
| MELDs | 28.8 | 0.108 | 16.3 | 0.163 |
| MELD-Nas | 21.2 | 0.115 | 12.8 | 0.171 |
| TPPMs | 18.6 | 0.110 | 13.4 | 0.172 |
COSSH-ACLF II score, Chinese Group on the Study of Severe Hepatitis B-ACLF II score; COSSH-ACLFs, Chinese Group on the Study of Severe Hepatitis B-ACLF score; CLIF-C ACLFs, CLIF-Consortium Acute-on-Chronic Liver Failure score; TPPMs, Tongji Prognostic Predictor Model score; MELDs, Model for End-Stage Liver Disease score; MELD-Nas, MELD-Sodium score.